Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications.
Epigenetics. 2017;12(5):323-339.
Fu L-L, Tian M, Li X, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug
discovery. Oncotarget. 2015;6(8):5501-5516.
Zhu H, Bengsch F, Svoronos N, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing
PD-L1 expression. Cell Rep. 2016;16(11):2829-2837.
Sahai V, Redig AJ, Collier KA, et al. Targeting BET bromodomain proteins in solid tumors. Oncotarget.
2016;7(33):53997-54009.
Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 2011;146(6):904-917.
Hogg SJ, Vervoort SJ, Deswal S, et al. BET-Bromodomain inhibitors engage the host immune system and regulate
expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18(9):2162-2174.